Neocryptotanshinone

Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza , inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathways In Vitro Neocryptotanshinone exhibits anti-inflammatory effect by suppression of NF-κB and iNOS signaling pathways. Neocryptotanshinone (10 μM and 20 μM, 24 h) inhibits LPS-induced iNOS protein expression in RAW264.7 cells. Neocryptotanshinone (20 μM, 24 h) shows no obvious cytotoxic effect towards murine RAW264.7 macrophages. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: RAW264.7 cells Concentration: 5, 10 and 20 μM Incubation Time: 24 hours Result: Inhibited LPS-induced cell viability in a dose-dependent manner. Western Blot AnalysisCell Line: RAW264.7 cells Concentration: 20 μM Incubation Time: 24 hours Result: Inhibited LPS-induced activation of NF-κB pathway and down-regulated LPS-induced expression of p-NF-κB p65, p-IκBα and p-IKKβ. In Vivo Neocryptotanshinone causes reversals of decreased pain thresholds induced by MSU treatment after 30, 60, and 120 min S. miltiorrhiza Bunge extract treatment (contains single active components). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MSU-induced pain model in male ICR mice (weighing 20-25 g)Dosage: 10, 25, 50 or 100 mg/kg Administration: Oral gavage; for 30, 60, 120 min Result: Inhibited inflammatory symptoms and nociceptive behaviors in a dose-dependent manner. Form:Solid IC50& Target:iNOS

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet